What is the recommended dosing and titration schedule for clomipramine (tricyclic antidepressant) in the treatment of Obsessive-Compulsive Disorder (OCD), including the maximum dose and tapering instructions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clomipramine Dosing and Titration for OCD

Starting Dose and Initial Titration

Start clomipramine at 25 mg daily and gradually increase to 100 mg over the first 2 weeks, then continue titrating up to a maximum of 250 mg daily (or 200 mg in children/adolescents), with the total daily dose given at bedtime after titration to minimize daytime sedation. 1

Week 1-2: Initial Phase

  • Begin with 25 mg daily, given in divided doses with meals to reduce gastrointestinal side effects 1
  • Increase gradually as tolerated to approximately 100 mg during the first 2 weeks 1
  • For children and adolescents, titrate to a maximum of 3 mg/kg or 100 mg (whichever is smaller) during this initial phase 1

Week 3 and Beyond: Continuation of Titration

  • After the first 2 weeks, continue increasing the dose gradually over several weeks up to a maximum of 250 mg daily in adults 1
  • For children and adolescents, the maximum is 3 mg/kg or 200 mg daily, whichever is smaller 1
  • Once titrated, give the entire daily dose at bedtime to minimize daytime sedation 1

Maximum Dose

  • Adults: 250 mg daily maximum 1
  • Children and adolescents: 200 mg daily or 3 mg/kg, whichever is smaller 1
  • Higher doses are associated with greater efficacy but also higher dropout rates due to adverse effects 2

Important Timing Considerations

  • Allow 2-3 weeks after each dosage change to reach steady-state plasma levels due to the long elimination half-lives of clomipramine and its active metabolite desmethylclomipramine 1
  • Assess efficacy after 8-12 weeks at the target dose, though some improvement may be seen within 2-4 weeks 2
  • Response is most often associated with doses greater than 75 mg/day 3

Tapering Down

When discontinuing clomipramine, taper gradually rather than stopping abruptly to avoid withdrawal symptoms, though specific tapering schedules are not provided in the FDA label. 1

Practical Tapering Approach

  • Given the long half-life (mean 39 hours) 4, a gradual taper over several weeks is prudent
  • Consider reducing by 25-50 mg every 1-2 weeks, monitoring for withdrawal symptoms
  • Slower tapers may be needed for patients on higher doses or those with longer treatment duration

Critical Safety Warnings

MAOI Interactions

  • Allow at least 14 days between discontinuing an MAOI and starting clomipramine 1
  • Allow at least 14 days after stopping clomipramine before starting an MAOI 1
  • Do not start clomipramine in patients receiving linezolid or intravenous methylene blue due to serotonin syndrome risk 1

Monitoring Requirements

  • Carefully assess adverse effects when establishing the optimal dose, as clomipramine has a less favorable side effect profile than SSRIs 2
  • Monitor for seizures and elevated aminotransferase values, which are potentially serious side effects 5
  • Sexual dysfunction and seizures may be more frequent with clomipramine than other tricyclics 4

Clinical Context

Clomipramine should be reserved as a second-line or third-line agent for OCD after at least one adequate SSRI trial has failed (8-12 weeks at maximum tolerated doses) 6. SSRIs are preferred first-line due to superior safety and tolerability profiles, which is critical for long-term treatment adherence 7, 2. While some meta-analyses suggest clomipramine may be more efficacious than SSRIs, head-to-head trials show equivalent efficacy, and earlier clomipramine trials enrolled less treatment-resistant patients 7, 2.

Maintenance Duration

  • Continue treatment for a minimum of 12-24 months after achieving remission due to high relapse rates after discontinuation 6, 2
  • Patients should be periodically reassessed to determine ongoing need for treatment 1
  • Dosage adjustments should maintain patients on the lowest effective dose 1

References

Guideline

Clomipramine Efficacy and Treatment Considerations for OCD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Treatment-Resistant OCD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.